Your browser doesn't support javascript.
loading
Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
Yanase, Tomonobu; Hatano, Masaru; Bujo, Chie; Tsuji, Masaki; Ishida, Junichi; Amiya, Eisuke; Okamoto, Koh; Ando, Masahiko; Shimada, Shogo; Kinoshita, Osamu; Fukushi, Shuetsu; Yamada, Souichi; Ono, Minoru; Komuro, Issei.
Afiliação
  • Yanase T; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Hatano M; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Bujo C; Advanced Medical Center for Heart Failure, The University of Tokyo Hospital.
  • Tsuji M; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Ishida J; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Amiya E; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Okamoto K; Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
  • Ando M; Department of Therapeutic Strategy for Heart Failure, The University of Tokyo.
  • Shimada S; Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo.
  • Kinoshita O; Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo.
  • Fukushi S; Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo.
  • Yamada S; Department of Cardiac Surgery, Graduate School of Medicine, The University of Tokyo.
  • Ono M; Department of Virology 1, National Institute of Infectious Diseases.
  • Komuro I; Department of Virology 1, National Institute of Infectious Diseases.
Int Heart J ; 64(1): 95-99, 2023 Mar 31.
Article em En | MEDLINE | ID: mdl-36682771
Currently available anti-cytomegalovirus (CMV) agents are sometimes poorly tolerated, owing to their side effects. Letermovir is a novel anti-CMV drug that is only approved for CMV prophylaxis in hematopoietic stem cell transplant recipients, with fewer side effects. We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully treated with off-label use of letermovir. In treating CMV infection or disease with letermovir, a transient rise or lag in the clearance of CMV-DNA polymerase chain reaction levels has been observed. Our case suggests that CMV-pp65 antigenemia can be an additional marker of treatment efficacy.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / Infecções por Citomegalovirus Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Coração / Infecções por Citomegalovirus Idioma: En Ano de publicação: 2023 Tipo de documento: Article